Purazo, Analyn D.
HRN: 01-56-84 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/17/2024
CO-AMOXICLAV 625MG (TAB)
02/17/2024
02/24/2024
ORAL
625mg/tab
TID
CAP
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes